Compare Amgen, Inc. (AMGN) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Sunrun Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Sunrun Inc trades at $12.46 (market cap $2.97B). The key difference: Amgen, Inc. is far larger — about 66× Sunrun Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| AMGN | RUN | |
|---|---|---|
Market Cap | $196.12B | $2.97B |
Sector | Health | Technology |
52-Week High | $388.16 | $21.41 |
52-Week Low | $271.18 | $9.07 |
Enterprise Value | $241.41B | $17.17B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Sunrun (RUN) trades at $12.47, up 0.08% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a net income margin of 17.88% and ROE of 19.06%, while launching a distributed AI data center pilot to leverage its home energy assets. Analyst consensus is bullish with a $17.45 price target, but cash flow from operations remains negative, highlighting financial strain.
The outlook for RUN is mixed: growth potential from virtual power plant initiatives and AI partnerships offers upside, but negative operating cash flow and high debt pose significant risks. Investors should weigh the attractive valuation multiples against operational sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
